Breaking News

LegenDay Starts Supplying High Precision Silicone Parts to Industrial Equipment

LegenDay Starts Supplying High Precision Silicone Parts to Industrial Equipment

Silicone Parts

SHENZHEN, China – December 1, 2022 – (

LegenDay today announced that it has started supplying industrial equipment’s high-precision silicone parts. These are a series of industrial-grade silicone accessories, such as protective caps, valves, micro seals, hose connectors, and gaskets – to mention a few.

LegenDay invested in a modern silicone parts production line to achieve tight tolerance and accuracy. The tolerance can range from +/- 0.003 inches to +/- 0.025 inches.

“Achieving tight tolerances with minimal secondary operations requires precision tool making and adopting dependable manufacturing technologies,” said Frank, LegenDay Marketing Manager. “At LegenDay, we produce exact and complex silicone parts with high-level consistency,” said Frank Bai Yue Hao, LegenDay Marketing Manager.

LegenDay adopts many silicone injection molding techniques, such as multi-shot, over molding, compression molding, 2k injection and extrusion. The company uses various silicone materials, including liquid silicone rubber (LSR), high-consistency silicone rubber (HCR) and regular silicone rubber. 

LegenDay uses a fully automated production line to manufacture high-precision silicone parts for accuracy and consistency. Through rigorous inspection, LegenDay silicone parts guarantee high performance, low defect rate, and high repeatability.

LegenDay supports OEM business and turnkey solutions in industrial equipment’s high-precision silicone parts. 

About LegenDay

LegenDay is a reputable and trusted silicone parts supplier. The company designs and tests every silicone part for unmatched performance in industrial equipment. With continued R&D and adopting the latest technologies, LegenDay remains a market leader in precision silicone parts. 

For more information:

Contact Person: Frank Bai Yue Hao (Sales Manager)
Email: [email protected]
Phone: +86 13430834223

Contact Information:

Frank Bai Yue Hao

LegenDay’s Marketing Manager
[email protected]

+86 13430834223

Press Release Service

Original Source:

LegenDay Starts Supplying High Precision Silicone Parts to Industrial Equipment

POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

BUFFALO, N.Y. – November 30, 2022 – (

POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2 clinical trial of EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes. Data from this clinical study has been published today in BMC Medicine (

EuCorVac-19 is an RBD-based vaccine consisting of POP BIO’s Spontaneous Nanoliposome Antigen Particle (SNAP) technology in combination with the adjuvant genetically modified E. coli Monophosphoryl Lipid A (EcML), produced by EuCorVac-19 manufacturer Eubiologics (KOSDAQ: 206650). Use of SNAP technology enables co-delivery, as opposed to co-administration, of antigen with adjuvant, packed in an immunogenic nanoparticle format free of any carrier protein. 

In this Phase II clinical study, 229 participants were enrolled at five clinical sites in South Korea. Healthy adults aged 19-75 without prior exposure to COVID-19 were dosed on day 0 and day 21 between July and October 2021. The most common local adverse events were low-grade injection site tenderness and pain, while the most common systemic adverse events were low-grade fatigue, myalgia, and headache. No clinical abnormalities were detected, and no serious adverse effects were solicited by EuCorVac-19. Adverse events did not increase with the second dosing. On day 42, Spike IgG geometric mean ELISA titers were 0.8, 211, and 590 Spike binding antibody units (BAU/mL) for placebo, low-dose, and high-dose EuCorVac-19, respectively (p

The published data shows that in this trial, EuCorVac-19 was well-tolerated and induced antibodies in a dose-dependent manner that neutralizes SARS-CoV-2. The unique liposome display approach of EuCorVac-19, which lacks any immunogenic protein components besides the antigen itself, coupled with the lack of increased adverse events during boosting suggests the vaccine platform is amenable to multiple boosting regimes in the future to help control the ongoing COVID-19 pandemic. 

“The results of this Phase II trial provide critical evidence of the value of the SNAP platform. This data provides invaluable support towards our platform’s development, further enabling the creation of new vaccines with the potential to alleviate suffering worldwide,” says POP BIO co-founder Jonathan Smyth.

“The unique qualities of the SNAP adjuvant system enabled simple conversion of protein antigens into immunogenic particles that safely induced virus-neutralizing antibodies. We look forward to further study of this technology for the prevention of COVID-19 and other diseases,” says company co-founder and study co-author Jonathan Lovell. 

Presently, EuCorVac-19 is undergoing two Phase III clinical studies in simultaneous studies in the Philippines and the Democratic Republic of Congo. EuBiologics is working with international research organizations to expedite recruitment and analyze trial results to accelerate regulatory approval of EuCorVac-19.

POP BIO is developing new vaccine product candidates and is seeking further collaborators around the SNAP technology to make use of the unique qualities of the vaccine platform technology.

POP Biotechnologies (POP BIO): POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from The State University of New York Research Foundation (SUNY-RF), was developed by company founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo).

POP BIO’s SNAP Technology: POP BIO’s Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of immunogenic particle-based vaccines and immunotherapies directed against infectious diseases and other diseases through the use of cobalt-modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle formation and liposome-display of protein and peptide antigens, resulting in substantial improvements in antigen-specific immune responses.

About EuBiologics: EuBiologics is a South Korean biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens and EcML. The total capacity of COVID-19 vaccine is in the hundreds of millions of doses per year.

About EuBiologics’ EuIMT Technology: EuBiologics’ Immune Modulation Technology uses genetically engineered Monophosphoryl Lipid A (MLA), termed EcML, a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems. Eubiologics’ EcML and POP BIO’s SNAP technologies synergize to create potent next-generation vaccines.

Contact Information:

Jonathan Smyth

[email protected]


Press Release Service

Original Source:

POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19